Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept

Rheumatology International

Volumn 39, Issue 2, 2019, Pages 239-243

  Generali, Elena ^a   Carrara, Greta ^b   Kallikourdis, Marinos ^a,c   Condorelli, Gianluigi ^a,c   Bortoluzzi, Alessandra ^d   Scirè, Carlo A ^b,d   Selmi, Carlo ^a,e  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Epidemiology Unit   (Italy)

^c HUMANITAS UNIVERSITY   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Biologic; Cardiovascular; DMARDs; Epidemiology

Indexed keywords

ABATACEPT; BIOLOGICAL PRODUCT; CORTICOSTEROID; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DATA BASE; DISEASE DURATION; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; AGED; COMPLICATION; RISK;

ABATACEPT; ADULT; AGED; ARTHRITIS, RHEUMATOID; ETANERCEPT; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85056312594     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-018-4196-9     Document Type: Article

References (20)

1. van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, Stehouwer CD, Spijkerman AM, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Smulders YM, Dijkmans BA, Nurmohamed MT (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68(9):1395–1400. 10.1136/ard.2008.094151
2. Pinheiro FA, Souza DC, Sato EI (2015) A study of multiple causes of death in rheumatoid arthritis. J Rheumatol. 10.3899/jrheum.150166
3. Schau T, Gottwald M, Arbach O, Seifert M, Schopp M, Neuss M, Butter C, Zanker M (2015) Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type. J Rheumatol 42(11):2029–2037. 10.3899/jrheum.141647
4. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16):2055–2059
5. Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323(4):236–241. 10.1056/NEJM199007263230405
6. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977. 10.1136/annrheumdis-2016-210715
7. Javed Q, Murtaza I (2013) Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ 22(5):323–327. 10.1016/j.hlc.2012.12.002
8. Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR (2013) Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis 72(11):1813–1818. 10.1136/annrheumdis-2012-202136
9. Rubbert-Roth A (2012) Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 51(suppl 5):38-47. 10.1093/rheumatology/kes114
10. Generali E, Carrara G, Selmi C, Verstappen S, Zambon A, Bortoluzzi A, Scirè C (2018) Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept. Clin Exp Rheumatol 36(2):310–313
11. Kallikourdis M, Martini E, Carullo P, Sardi C, Roselli G, Greco CM, Vignali D, Riva F, Ormbostad Berre AM, Stolen TO, Fumero A, Faggian G, Di Pasquale E, Elia L, Rumio C, Catalucci D, Papait R, Condorelli G (2017) T cell costimulation blockade blunts pressure overload-induced heart failure. Nat Commun 8:14680. 10.1038/ncomms14680
12. Carrara G, Scire CA, Zambon A, Cimmino MA, Cerra C, Caprioli M, Cagnotto G, Nicotra F, Arfe A, Migliazza S, Corrao G, Minisola G, Montecucco C (2015) A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case-control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology. BMJ Open 5(1):e006029. 10.1136/bmjopen-2014-006029
13. Corrao G, Ghirardi A, Ibrahim B, Merlino L, Maggioni AP (2014) Burden of new hospitalization for heart failure: a population-based investigation from Italy. Eur J Heart Fail 16(7):729–736. 10.1002/ejhf.105
14. Nevers T, Salvador AM, Grodecki-Pena A, Knapp A, Velazquez F, Aronovitz M, Kapur NK, Karas RH, Blanton RM, Alcaide P (2015) Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail 8(4):776–787. 10.1161/CIRCHEARTFAILURE.115.002225
15. Selmi C, Ceribelli A, Naguwa SM, Cantarini L, Shoenfeld Y (2015) Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf 14(3):389–399. 10.1517/14740338.2015.993605
16. Silvagni E, Bortoluzzi A, Carrara G, Zanetti A, Govoni M, Scire CA (2018) Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases. BMJ Open 8(9):e021447. 10.1136/bmjopen-2017-021447
17. Carrara G, Bortoluzzi A, Sakellariou G, Silvagni E, Zanetti A, Govoni M, Scire CA (2018) Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology. Clin Exp Rheumatol [Epub ahead of print]
18. Caprioli M, Carrara G, Sakellariou G, Silvagni E, Scire CA (2017) Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open 3(2):e000523. 10.1136/rmdopen-2017-000523
19. Buttgereit JWJB F (2016) Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies. Rheumatology 55(suppl 2):ii3–ii5. 10.1093/rheumatology/kew344
20. Ajeganova S, Svensson B, Hafstrom I, Group BS (2014) Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open 4(4):e004259. 10.1136/bmjopen-2013-004259